Expanding the Promise of RNA Therapies

RNA therapies and vaccines have already shown their power. Nutcracker Therapeutics is taking a nod from the high-tech sector to harness semiconductor-like biochips and microfluidic engineering to create a fully automated platform to increase the speed and scale at which RNA therapies can be discovered, developed, and manufactured. It is developing multimodal RNA therapies which serves as an RNA cocktail to attack multiple disease mechanisms at once. We spoke to Geoff Nosrati, chief business officer of Nutcracker, about the company’s platform technology, its lead program targeting HPV-driven tumors, and its focus on multimodal RNA therapies.